Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 58 30 6 17
Adverse Event Associated with Cardiac Arrhythmia 74
Premature Cardiac Complex 74
Extrasystoles 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
cardiac arrhythmia:
Clinical modifier sudden death
Inheritance autosomal dominant inheritance


External Ids:

OMIM 58 115000
MedGen 43 C0003811
SNOMED-CT via HPO 70 263681008 26636000 88425004

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac conduction defect and long qt syndrome 13, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is TANGO2 (Transport And Golgi Organization 2 Homolog), and among its related pathways/superpathways are Circadian entrainment and Aldosterone synthesis and secretion. The drugs Methadone and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

Description from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 276)
# Related Disease Score Top Affiliating Genes
1 cardiac conduction defect 31.9 KCNH2 KCNQ1 RYR2 SCN5A
2 long qt syndrome 13 31.6 KCNH2 KCNQ1 SCN5A
3 long qt syndrome 9 31.6 KCNJ2 SCN5A
4 long qt syndrome 3 31.2 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
5 brugada syndrome 1 31.0 KCNH2 SCN5A
6 long qt syndrome 12 30.9 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
7 familial short qt syndrome 30.6 KCNH2 KCNJ2 KCNQ1
8 long qt syndrome 2 30.5 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
9 ventricular fibrillation, paroxysmal familial, 1 30.2 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
10 sudden infant death syndrome 30.2 KCNH2 KCNQ1 RYR2 SCN5A
11 syncope 30.0 KCNH2 KCNJ2 KCNQ1 SCN5A
12 long qt syndrome 5 30.0 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
13 sick sinus syndrome 30.0 CACNA1C RANGRF SCN5A
14 long qt syndrome 1 29.8 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
15 long qt syndrome 6 29.8 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
16 cardiac arrest 29.8 ANK2 KCNH2 KCNQ1 RYR2 SCN5A
17 brugada syndrome 29.6 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1
18 arrhythmogenic right ventricular cardiomyopathy 29.5 ANK2 KCNH2 RYR2 SCN5A
19 hypertrophic cardiomyopathy 29.5 CACNA1C RYR2 SCN5A
20 right bundle branch block 29.3 CACNA1C SCN5A
21 atrioventricular block 29.2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
22 catecholaminergic polymorphic ventricular tachycardia 29.1 ANK2 KCNH2 KCNJ2 RYR2 SCN5A
23 hypokalemic periodic paralysis, type 1 29.1 CACNA1C KCNJ2
24 heart disease 29.0 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 RYR2
25 dilated cardiomyopathy 28.8 CACNA1C KCNH2 KCNQ1 RYR2 SCN5A
26 atrial fibrillation 28.8 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
27 jervell and lange-nielsen syndrome 1 28.3 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
28 long qt syndrome 28.3 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
29 intellectual developmental disorder with cardiac arrhythmia 12.7
30 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 12.6
31 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.6
32 cardiac arrhythmia, ankyrin-b-related 12.6
33 extrasystoles, multiform ventricular, with short stature, hyperpigmentation and microcephaly 12.1
34 ventricular extrasystoles with syncope, perodactyly, and robin sequence 12.1
35 extrasystoles short stature hyperpigmentation microcephaly 12.1
36 muscular dystrophy, limb-girdle, autosomal recessive 25 12.0
37 ogden syndrome 11.8
38 tango2-related metabolic encephalopathy and arrhythmias 11.7
39 myotonic dystrophy 1 11.3
40 spondylometaphyseal dysplasia, sedaghatian type 11.3
41 hand and foot deformity with flat facies 11.2
42 carnitine palmitoyltransferase ii deficiency, lethal neonatal 11.2
43 thyrotoxic periodic paralysis 11.2
44 arrhythmogenic right ventricular dysplasia, familial, 1 11.0
45 refsum disease, classic 11.0
46 heterotaxy, visceral, 1, x-linked 11.0
47 cardiomyopathy, infantile histiocytoid 11.0
48 hypomagnesemia 1, intestinal 11.0
49 myotonic dystrophy 2 11.0
50 arrhythmogenic right ventricular dysplasia, familial, 8 11.0

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Ischemic Heart Disease Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Human phenotypes related to Cardiac Arrhythmia:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 33 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 33 HP:0006696

Symptoms via clinical synopsis from OMIM:

58
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death

Clinical features from OMIM:

115000

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 BVES CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1
2 muscle MP:0005369 9.23 BVES CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methadone Approved, Illicit Phase 4 76-99-3 4095
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
4
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 51-43-4 5816
5
Racepinephrine Approved Phase 4,Phase 1,Not Applicable 329-65-7 838
6
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
7
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
8
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
9
Milrinone Approved Phase 4,Phase 2 78415-72-2 4197
10
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
12
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
13
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
14
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 5311068 68602
15 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
16
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
17
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 437-38-7 3345
19
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
20
Atropine Approved, Vet_approved Phase 4,Phase 2 5908-99-6, 51-55-8 174174
21
Ajmaline Approved, Experimental Phase 4 4360-12-7 441080
22
Procainamide Approved Phase 4,Phase 3,Not Applicable 51-06-9 4913
23
Carbetocin Approved, Investigational Phase 4,Not Applicable 37025-55-1 16681432 71715
24
Oxytocin Approved, Vet_approved Phase 4,Early Phase 1,Not Applicable 50-56-6 53477758 439302
25
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
26
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
27
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
28
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
29
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
30
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
31
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
32
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
33
Phylloquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 84-80-0
34
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
35 Menaquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 1182-68-9
36
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 54678486 6691
37
Morphine Approved, Investigational Phase 4 57-27-2 5288826
38
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
39
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
40
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
41
Ibutilide Approved Phase 4,Phase 2,Not Applicable 122647-31-8, 122647-32-9 60753
42
Metoprolol Approved, Investigational Phase 4,Not Applicable 37350-58-6, 51384-51-1 4171
43
Magnesium oxide Approved Phase 4,Not Applicable 1309-48-4 14792
44
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-04-2
45
Magnesium citrate Approved Phase 4,Not Applicable 3344-18-1
46
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
47
nivolumab Approved Phase 4 946414-94-4
48
Atorvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 134523-00-5 60823
49
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
50
Eplerenone Approved Phase 4,Phase 3 107724-20-9 443872 150310

Interventional clinical trials:

(show top 50) (show all 941)
# Name Status NCT ID Phase Drugs
1 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
2 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
3 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
4 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
5 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
6 Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Completed NCT00702117 Phase 4 flecainide;ajmaline;procainamide
7 Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD Completed NCT00729911 Phase 4 Amiodarone
8 Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study Recruiting NCT03716076 Phase 4 Carbetocin
9 Reveal® XT Performance Trial (XPECT) Completed NCT00680927 Phase 4
10 Genetics of QT Response to Moxifloxacin Enrolling by invitation NCT01936480 Phase 4 Moxifloxacin 400mg once time;Placebo
11 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
12 Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) Recruiting NCT03346057 Phase 4 Sugammadex 2 mg/kg;Sugammadex 4 mg/kg;Sugammadex 16 mg/kg;Neostigmine + Glycopyrrolate
13 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
14 Radiation Exposure Reduction in Supraventricular Tachycardia Ablation Completed NCT01132274 Phase 4
15 Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study - Completed NCT00848445 Phase 4
16 Targeted Potassium Levels for Prevention of ICD Therapy Not yet recruiting NCT03833089 Phase 4
17 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
18 Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management Completed NCT02335398 Phase 4 Methadone
19 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
20 Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation Recruiting NCT02426944 Phase 4 NOAC
21 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
22 Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter Completed NCT01448265 Phase 4
23 Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients Completed NCT01085071 Phase 4 Potassium Chloride;Potassium Chloride
24 Anticoagulation in AF Ablation and Effects on Neurocognitive Function Withdrawn NCT02120560 Phase 4
25 Open-Labeled PK-PD Studies of Metoprolol ER Active, not recruiting NCT02417246 Phase 4 Toprol XL;Wockhardt metoprolol;Activas metoprolol
26 Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias Completed NCT00765713 Phase 4
27 Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation Completed NCT00247780 Phase 4
28 The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects Completed NCT00994006 Phase 4
29 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL Recruiting NCT03584087 Phase 4 Normal Saline;Terlipressin
30 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
31 Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI Recruiting NCT02590653 Phase 4 Atorvastatin
32 Atrial Fibrillation and Congestive Heart Failure Trial Completed NCT00597077 Phase 4
33 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4 amiodarone;Placebo
34 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
35 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation Completed NCT00552084 Phase 4 Fish oil;Placebo
36 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart Completed NCT02415400 Phase 4 Apixaban;vitamin K antagonist;Acetylsalicylic acid
37 Hemodynamic Responses to Tracheal Intubation Direct Laryngoscope and Videolaryngoscope in Elderly Patients Completed NCT02816775 Phase 4
38 Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction Completed NCT01176968 Phase 4 Eplerenone;Placebo
39 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
40 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter Completed NCT01914926 Phase 4 Metoprolol;Diltiazem
41 Milrinone Versus Dobutamine in Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
42 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
43 (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes Not yet recruiting NCT03796195 Phase 4 .5% Bupivacaine
44 Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation Completed NCT03140631 Phase 4 Protamine Sulfate
45 The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation. Terminated NCT00232271 Phase 4 Clexane
46 Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol Terminated NCT01404767 Phase 4 Esmolol;Metoprolol
47 Study of Optimal Replacement of Thyroxine in the Elderly Completed NCT01647750 Phase 4 Levothyroxine;Levothyroxine
48 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
49 Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol Completed NCT01174290 Phase 4 Haloperidol decanoate;Placebo
50 The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery Completed NCT03054857 Phase 4 Dexmedetomidine;Placebo

Search NIH Clinical Center for Cardiac Arrhythmia

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 30

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

42
Heart, Kidney, Testes, Brain, Lung, Endothelial, Bone

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 791)
# Title Authors Year
1
Wearable devices for cardiac arrhythmia detection: a new contender? ( 31083804 )
2019
2
An Efficient Cardiac Arrhythmia Onset Detection Technique Using a Novel Feature Rank Score Algorithm. ( 31056739 )
2019
3
Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review. ( 31045463 )
2019
4
Synthetic Cannabinoids and Cardiac Arrhythmia Risk: Review of the Literature. ( 31030341 )
2019
5
Combining deep neural networks and engineered features for cardiac arrhythmia detection from ECG recordings. ( 30943458 )
2019
6
Cardiac arrhythmia and opioids: Be watchful. ( 30885377 )
2019
7
Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). ( 30882141 )
2019
8
Loperamide induced cardiac arrhythmia successfully supported with veno-arterial ECMO (VA-ECMO), molecular adsorbent recirculating system (MARS) and continuous renal replacement therapy (CRRT). ( 30806091 )
2019
9
Amiodarone and acupuncture for cardiac arrhythmia: Study protocol for a systematic review. ( 30762798 )
2019
10
Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. ( 30747032 )
2019
11
Cardiac arrhythmia considerations of hormone cancer therapies. ( 30698686 )
2019
12
A Case of Cardiac Arrhythmia from Absorption of Normal Saline during Hysteroscopic Myomectomy. ( 30267897 )
2019
13
European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). ( 29905786 )
2019
14
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). ( 30052888 )
2019
15
Effects of hawthorn ( Crataegus pentagyna) leaf extract on electrophysiologic properties of cardiomyocytes derived from human cardiac arrhythmia-specific induced pluripotent stem cells. ( 29133340 )
2018
16
Promoting cardiac arrhythmia care in Africa: a big challenge that begins with data. ( 29309583 )
2018
17
Intellectual developmental disorder with cardiac arrhythmia syndrome in a child with compound heterozygous GNB5 variants. ( 29368331 )
2018
18
Retrospective multi-phase non-contrast-enhanced magnetic resonance angiography (ROMANCE MRA) for robust angiogram separation in the presence of cardiac arrhythmia. ( 29427402 )
2018
19
Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. ( 29531724 )
2018
20
Is exposure to ionising radiation associated with childhood cardiac arrhythmia in the Russian territories contaminated by the Chernobyl fallout? A cross-sectional population-based study. ( 29581199 )
2018
21
Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP). ( 29619247 )
2018
22
Amiodarone for the Successful Management of Caowu Poisoning - Induced Cardiac Arrhythmia. ( 29643705 )
2018
23
Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. ( 29678624 )
2018
24
Multiclass Classification of Cardiac Arrhythmia Using Improved Feature Selection and SVM Invariants. ( 29692863 )
2018
25
Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part I: development of congenital cardiology, epidemiology, clinical aspects, heart failure, cardiac arrhythmia. ( 30740318 )
2018
26
Temperature variability and hospitalization for cardiac arrhythmia in Brazil: A nationwide case-crossover study during 2000-2015. ( 30594895 )
2018
27
Pacemaker implantation for treating migraine-like headache secondary to cardiac arrhythmia: A case report. ( 30558049 )
2018
28
Statin use is associated with less postoperative cardiac arrhythmia after total hip arthroplasty. ( 30526117 )
2018
29
Real-Time Cardiac Arrhythmia Classification Using Memristor Neuromorphic Computing System. ( 30440932 )
2018
30
Noninvasive cardiac arrhythmia ablation with particle beams. ( 30421810 )
2018
31
A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression. ( 30380381 )
2018
32
Machine-Learning Prediction of Drug-Induced Cardiac Arrhythmia: Analysis of Gene Expression and Clustering. ( 30311557 )
2018
33
Aconitine-induced cardiac arrhythmia in human induced pluripotent stem cell-derived cardiomyocytes. ( 30233701 )
2018
34
Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia? ( 30205603 )
2018
35
Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). ( 30137444 )
2018
36
A Heart for Diversity: Simulating Variability in Cardiac Arrhythmia Research. ( 30079031 )
2018
37
Opioids and Cardiac Arrhythmia: A Literature Review. ( 30071529 )
2018
38
Mutations in voltage-gated L-type calcium channel: implications in cardiac arrhythmia. ( 30027834 )
2018
39
Effects of Pinocembrin Pretreatment on Connexin 43 (Cx43) Protein Expression After Rat Myocardial Ischemia-Reperfusion and Cardiac Arrhythmia. ( 30022020 )
2018
40
The effect of ambient particle matters on hospital admissions for cardiac arrhythmia: a multi-city case-crossover study in China. ( 30012150 )
2018
41
Transesophageal 2D ultrasound to 3D computed tomography registration for the guidance of a cardiac arrhythmia therapy. ( 29992909 )
2018
42
Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients. ( 29970732 )
2018
43
Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. ( 29961863 )
2018
44
Design of a hybrid model for cardiac arrhythmia classification based on Daubechies wavelet transform. ( 29877638 )
2018
45
Kcne4 deletion sex-specifically predisposes to cardiac arrhythmia via testosterone-dependent impairment of RISK/SAFE pathway induction in aged mice. ( 29844497 )
2018
46
Status of cardiac arrhythmia services in Africa in 2018: a PASCAR Sudden Cardiac Death Task Force report. ( 29745966 )
2018
47
Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis. ( 29740922 )
2018
48
Cardiac Arrhythmia Classification by Multi-Layer Perceptron and Convolution Neural Networks. ( 29734666 )
2018
49
Conventional Acupuncture for Cardiac Arrhythmia: A Systematic Review of Randomized Controlled Trials. ( 28432528 )
2018
50
Anxiety in children attending a specialist inherited cardiac arrhythmia clinic: a questionnaire study. ( 30234175 )
2018

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6 (show top 50) (show all 200)
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNE2 NM_172201.1(KCNE2): c.161T> C (p.Met54Thr) single nucleotide variant risk factor rs74315447 GRCh37 Chromosome 21, 35742938: 35742938
2 KCNE2 NM_172201.1(KCNE2): c.161T> C (p.Met54Thr) single nucleotide variant risk factor rs74315447 GRCh38 Chromosome 21, 34370639: 34370639
3 KCNE2 NM_172201.1(KCNE2): c.170T> C (p.Ile57Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs74315448 GRCh37 Chromosome 21, 35742947: 35742947
4 KCNE2 NM_172201.1(KCNE2): c.170T> C (p.Ile57Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs74315448 GRCh38 Chromosome 21, 34370648: 34370648
5 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh37 Chromosome 3, 38620907: 38620907
6 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh38 Chromosome 3, 38579416: 38579416
7 ANK2 NM_001148.4(ANK2): c.11231C> A (p.Thr3744Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs121912705 GRCh37 Chromosome 4, 114288920: 114288920
8 ANK2 NM_001148.4(ANK2): c.11231C> A (p.Thr3744Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs121912705 GRCh38 Chromosome 4, 113367764: 113367764
9 ANK2 NM_001148.4(ANK2): c.11218C> A (p.Leu3740Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs35530544 GRCh37 Chromosome 4, 114288907: 114288907
10 ANK2 NM_001148.4(ANK2): c.11218C> A (p.Leu3740Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs35530544 GRCh38 Chromosome 4, 113367751: 113367751
11 ANK2 NM_001148.4(ANK2): c.11716C> T (p.Arg3906Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912706 GRCh37 Chromosome 4, 114294462: 114294462
12 ANK2 NM_001148.4(ANK2): c.11716C> T (p.Arg3906Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912706 GRCh38 Chromosome 4, 113373306: 113373306
13 ANK2 NM_001148.4(ANK2): c.11791G> A (p.Glu3931Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45454496 GRCh37 Chromosome 4, 114294537: 114294537
14 ANK2 NM_001148.4(ANK2): c.11791G> A (p.Glu3931Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45454496 GRCh38 Chromosome 4, 113373381: 113373381
15 ANK2 NM_001127493.1(ANK2): c.321+19C> T single nucleotide variant Benign rs45502093 GRCh37 Chromosome 4, 114120284: 114120284
16 ANK2 NM_001127493.1(ANK2): c.3769+18G> A single nucleotide variant Uncertain significance rs66792339 GRCh38 Chromosome 4, 113336799: 113336799
17 AKAP9 NM_147185.2(AKAP9): c.4837A> G (p.Met1613Val) single nucleotide variant Conflicting interpretations of pathogenicity rs193922723 GRCh37 Chromosome 7, 91670132: 91670132
18 AKAP9 NM_147185.2(AKAP9): c.4837A> G (p.Met1613Val) single nucleotide variant Conflicting interpretations of pathogenicity rs193922723 GRCh38 Chromosome 7, 92040818: 92040818
19 ANK2 NM_001127493.1(ANK2): c.3483A> G (p.Val1161=) single nucleotide variant Benign/Likely benign rs35336373 GRCh37 Chromosome 4, 114257132: 114257132
20 ANK2 NM_001127493.1(ANK2): c.3483A> G (p.Val1161=) single nucleotide variant Benign/Likely benign rs35336373 GRCh38 Chromosome 4, 113335976: 113335976
21 ANK2 NM_001127493.1(ANK2): c.3769+18G> A single nucleotide variant Uncertain significance rs66792339 GRCh37 Chromosome 4, 114257955: 114257955
22 ANK2 NM_001127493.1(ANK2): c.321+19C> T single nucleotide variant Benign rs45502093 GRCh38 Chromosome 4, 113199128: 113199128
23 ANK2 NM_001148.4(ANK2): c.7106T> C (p.Val2369Ala) single nucleotide variant Benign/Likely benign rs28377576 GRCh37 Chromosome 4, 114276880: 114276880
24 ANK2 NM_001148.4(ANK2): c.7106T> C (p.Val2369Ala) single nucleotide variant Benign/Likely benign rs28377576 GRCh38 Chromosome 4, 113355724: 113355724
25 ANK2 NM_001127493.1(ANK2): c.4400-4039G> A single nucleotide variant Conflicting interpretations of pathogenicity rs193922637 GRCh37 Chromosome 4, 114277940: 114277940
26 ANK2 NM_001127493.1(ANK2): c.4400-4039G> A single nucleotide variant Conflicting interpretations of pathogenicity rs193922637 GRCh38 Chromosome 4, 113356784: 113356784
27 ATP1B1; NME7 NM_001677.3(ATP1B1): c.571C> T (p.Pro191Ser) single nucleotide variant Uncertain significance rs267598155 GRCh37 Chromosome 1, 169099251: 169099251
28 ATP1B1; NME7 NM_001677.3(ATP1B1): c.571C> T (p.Pro191Ser) single nucleotide variant Uncertain significance rs267598155 GRCh38 Chromosome 1, 169130013: 169130013
29 ATP1B1; NME7 NM_001677.3(ATP1B1): c.571C> T (p.Pro191Ser) single nucleotide variant Uncertain significance rs267598155 NCBI36 Chromosome 1, 167365875: 167365875
30 CACNA1C NM_000719.6(CACNA1C): c.171C> T (p.Asp57=) single nucleotide variant Benign/Likely benign rs34419050 GRCh37 Chromosome 12, 2224511: 2224511
31 CACNA1C NM_000719.6(CACNA1C): c.171C> T (p.Asp57=) single nucleotide variant Benign/Likely benign rs34419050 GRCh38 Chromosome 12, 2115345: 2115345
32 CACNA1C NM_000719.6(CACNA1C): c.372-15G> A single nucleotide variant Benign/Likely benign rs55792866 GRCh37 Chromosome 12, 2229476: 2229476
33 CACNA1C NM_000719.6(CACNA1C): c.372-15G> A single nucleotide variant Benign/Likely benign rs55792866 GRCh38 Chromosome 12, 2120310: 2120310
34 CACNA1C NM_000719.6(CACNA1C): c.5680+15C> T single nucleotide variant Benign/Likely benign rs114036394 GRCh37 Chromosome 12, 2795023: 2795023
35 CACNA1C NM_000719.6(CACNA1C): c.5680+15C> T single nucleotide variant Benign/Likely benign rs114036394 GRCh38 Chromosome 12, 2685857: 2685857
36 CACNA1C NM_000719.6(CACNA1C): c.6031G> A (p.Val2011Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs193922615 GRCh37 Chromosome 12, 2797859: 2797859
37 CACNA1C NM_000719.6(CACNA1C): c.6031G> A (p.Val2011Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs193922615 GRCh38 Chromosome 12, 2688693: 2688693
38 CACNA1C NM_000719.6(CACNA1C): c.6307G> T (p.Ala2103Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs193922616 GRCh37 Chromosome 12, 2800255: 2800255
39 CACNA1C NM_000719.6(CACNA1C): c.6307G> T (p.Ala2103Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs193922616 GRCh38 Chromosome 12, 2691089: 2691089
40 CASQ2 NM_001232.3(CASQ2): c.731A> G (p.His244Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28730716 GRCh37 Chromosome 1, 116269619: 116269619
41 CASQ2 NM_001232.3(CASQ2): c.731A> G (p.His244Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28730716 GRCh38 Chromosome 1, 115726998: 115726998
42 DSG2 NM_001943.4(DSG2): c.3135A> C (p.Thr1045=) single nucleotide variant Benign rs8095704 GRCh37 Chromosome 18, 29126484: 29126484
43 DSG2 NM_001943.4(DSG2): c.3135A> C (p.Thr1045=) single nucleotide variant Benign rs8095704 GRCh38 Chromosome 18, 31546521: 31546521
44 JUP NM_021991.3(JUP): c.1774-13C> T single nucleotide variant Benign/Likely benign rs116772523 GRCh37 Chromosome 17, 39914049: 39914049
45 JUP NM_021991.3(JUP): c.1774-13C> T single nucleotide variant Benign/Likely benign rs116772523 GRCh38 Chromosome 17, 41757797: 41757797
46 JUP NM_021991.3(JUP): c.867C> T (p.Thr289=) single nucleotide variant Benign/Likely benign rs2230407 GRCh37 Chromosome 17, 39923673: 39923673
47 JUP NM_021991.3(JUP): c.867C> T (p.Thr289=) single nucleotide variant Benign/Likely benign rs2230407 GRCh38 Chromosome 17, 41767421: 41767421
48 JUP NM_002230.2(JUP): c.909+6C> T single nucleotide variant Conflicting interpretations of pathogenicity rs193922705 GRCh37 Chromosome 17, 39923625: 39923625
49 JUP NM_002230.2(JUP): c.909+6C> T single nucleotide variant Conflicting interpretations of pathogenicity rs193922705 GRCh38 Chromosome 17, 41767373: 41767373
50 KCNE1 NM_000219.5(KCNE1): c.30G> T (p.Thr10=) single nucleotide variant Likely benign rs187686559 GRCh37 Chromosome 21, 35821903: 35821903

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 CACNA1C GNB5 KCNJ2 KCNQ1 RYR2
2
Show member pathways
12.67 CACNA1C KCNE1 KCNQ1 RYR2 SCN5A
3
Show member pathways
12.34 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 12.16 CACNA1C GNB5 KCNE1 KCNE2 KCNH2 KCNJ2
5 11.88 KCNH2 KCNQ1 RYR2 SCN5A
6
Show member pathways
11.87 KCNE2 KCNJ2 KCNQ1
7
Show member pathways
11.8 KCNH2 KCNJ2 KCNQ1
8
Show member pathways
11.51 CACNA1C KCNE1 KCNE2 KCNQ1 RANGRF SCN5A
9 11.02 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
10 10.97 ANK2 SCN5A
11 10.78 KCNE1 KCNJ2 KCNQ1

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.81 KCNE1 KCNE2 KCNH2 SCN5A
2 lysosome GO:0005764 9.76 ANK2 KCNE1 KCNE2 KCNQ1
3 membrane raft GO:0045121 9.67 ANK2 KCNE1 KCNQ1
4 caveola GO:0005901 9.58 BVES RANGRF SCN5A
5 intercalated disc GO:0014704 9.56 ANK2 KCNJ2 RANGRF SCN5A
6 Z disc GO:0030018 9.55 ANK2 CACNA1C KCNE1 RYR2 SCN5A
7 T-tubule GO:0030315 9.54 ANK2 KCNJ2 SCN5A
8 smooth endoplasmic reticulum GO:0005790 9.48 KCNJ2 RYR2
9 sarcolemma GO:0042383 9.35 ANK2 BVES CACNA1C RYR2 SCN5A
10 voltage-gated potassium channel complex GO:0008076 9.02 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
11 membrane GO:0016020 10.21 ANK2 BVES CACNA1C GNB5 KCNE1 KCNE2
12 plasma membrane GO:0005886 10.1 ANK2 BVES CACNA1C GNB5 KCNE1 KCNE2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.97 CACNA1C KCNQ1 RYR2 SCN5A
2 potassium ion transport GO:0006813 9.96 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
3 potassium ion transmembrane transport GO:0071805 9.95 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 regulation of ion transmembrane transport GO:0034765 9.91 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
5 cardiac muscle contraction GO:0060048 9.87 KCNH2 KCNQ1 RYR2 SCN5A
6 regulation of membrane potential GO:0042391 9.86 BVES KCNH2 RANGRF
7 cellular response to drug GO:0035690 9.83 KCNE2 KCNH2 KCNQ1
8 positive regulation of potassium ion transmembrane transport GO:1901381 9.83 KCNE1 KCNH2 KCNJ2 KCNQ1
9 potassium ion export across plasma membrane GO:0097623 9.81 KCNE1 KCNE2 KCNH2 KCNQ1
10 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.8 KCNE1 KCNE2 KCNH2 KCNQ1
11 regulation of heart rate GO:0002027 9.8 ANK2 BVES RANGRF RYR2 SCN5A
12 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.78 ANK2 CACNA1C RYR2
13 regulation of membrane repolarization GO:0060306 9.78 KCNE2 KCNH2 KCNJ2 KCNQ1
14 regulation of potassium ion transmembrane transport GO:1901379 9.77 KCNE1 KCNE2 KCNH2
15 regulation of cardiac muscle cell contraction GO:0086004 9.77 ANK2 KCNJ2 SCN5A
16 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.76 CACNA1C KCNJ2 SCN5A
17 membrane repolarization GO:0086009 9.76 KCNE1 KCNE2 KCNH2 KCNQ1
18 atrial cardiac muscle cell action potential GO:0086014 9.75 ANK2 KCNQ1 SCN5A
19 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.73 KCNE1 KCNH2 KCNJ2 KCNQ1
20 cardiac muscle cell action potential involved in contraction GO:0086002 9.72 CACNA1C KCNE1 KCNE2 KCNJ2 SCN5A
21 potassium ion import across plasma membrane GO:1990573 9.7 KCNE2 KCNJ2
22 positive regulation of heart rate GO:0010460 9.7 KCNQ1 RYR2
23 regulation of cardiac muscle contraction GO:0055117 9.69 ANK2 RYR2
24 membrane depolarization during action potential GO:0086010 9.69 KCNH2 SCN5A
25 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.68 KCNE1 KCNE2
26 calcium ion transport into cytosol GO:0060402 9.68 CACNA1C RYR2
27 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.68 CACNA1C RYR2
28 cellular response to epinephrine stimulus GO:0071872 9.68 KCNQ1 RYR2
29 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.67 CACNA1C RYR2
30 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.67 ANK2 RYR2
31 regulation of sodium ion transmembrane transport GO:1902305 9.66 RANGRF SCN5A
32 regulation of delayed rectifier potassium channel activity GO:1902259 9.65 KCNE1 KCNE2
33 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.65 KCNQ1 SCN5A
34 membrane repolarization during action potential GO:0086011 9.65 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
35 SA node cell action potential GO:0086015 9.64 ANK2 SCN5A
36 membrane depolarization during AV node cell action potential GO:0086045 9.64 CACNA1C SCN5A
37 membrane depolarization during SA node cell action potential GO:0086046 9.63 ANK2 SCN5A
38 sarcoplasmic reticulum calcium ion transport GO:0070296 9.63 ANK2 RYR2
39 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.63 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
40 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.62 CACNA1C SCN5A
41 regulation of atrial cardiac muscle cell action potential GO:0098910 9.62 ANK2 RYR2
42 regulation of SA node cell action potential GO:0098907 9.61 ANK2 RYR2
43 regulation of heart rate by cardiac conduction GO:0086091 9.56 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
44 ventricular cardiac muscle cell action potential GO:0086005 9.17 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
45 ion transport GO:0006811 10.14 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
46 transmembrane transport GO:0055085 10.06 CACNA1C KCNH2 KCNQ1 RYR2 SCN5A

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.78 CACNA1C KCNQ1 RYR2 SCN5A
2 ion channel activity GO:0005216 9.76 CACNA1C KCNH2 RYR2 SCN5A
3 potassium channel activity GO:0005267 9.71 KCNE1 KCNE2 KCNH2 KCNQ1
4 scaffold protein binding GO:0097110 9.67 KCNH2 KCNQ1 SCN5A
5 voltage-gated potassium channel activity GO:0005249 9.67 KCNE1 KCNE2 KCNH2 KCNQ1
6 voltage-gated ion channel activity GO:0005244 9.63 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
7 delayed rectifier potassium channel activity GO:0005251 9.62 KCNE1 KCNE2 KCNH2 KCNQ1
8 inward rectifier potassium channel activity GO:0005242 9.61 KCNE2 KCNH2 KCNJ2
9 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.56 KCNE1 KCNE2 KCNH2 KCNQ1
10 potassium channel regulator activity GO:0015459 9.54 KCNE1 KCNE2
11 protein kinase A regulatory subunit binding GO:0034237 9.52 KCNQ1 RYR2
12 protein kinase A catalytic subunit binding GO:0034236 9.51 KCNQ1 RYR2
13 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.26 KCNE1 KCNH2 KCNJ2 KCNQ1
14 ion channel binding GO:0044325 9.17 ANK2 KCNE1 KCNE2 KCNQ1 RANGRF RYR2

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....